hydroquinone has been researched along with Chloasma in 133 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the use of a nonablative, fractional, 1,927-nm diode laser with and without topical 2% hydroquinone (HQ) cream for moderate-to-severe facial hyperpigmentation in Fitzpatrick skin Types III-V." | 9.27 | The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. ( Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018) |
| "To observe and analyze the efficacy of tranexamic acid combined with reduced glutathione in chloasma treatment." | 9.27 | Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma. ( Feng, C; Yan, M, 2018) |
| "Determine the efficacy and tolerability of a topical, non-hydroquinone, non-retinol pigment-correcting serum (LYT2) for the treatment of pregnancy-induced melasma." | 8.12 | Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum. ( Jiang, LI; Makino, ET; Mehta, RC; Mikati, M; Stephens, TJ, 2022) |
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 7.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| " Three cases of suspected hydroquinone-induced exogenous ochronosis while treating melasma were subjected to dermatoscopy and histopathology studies." | 7.79 | Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. ( Deshpande, DJ; Dhurat, RS; Mishra, SN; Nayak, CS, 2013) |
| "Although bleaching treatment using all-trans retinoic acid (RA) and hydroquinone (HQ) improves epidermal melanosis, the application of two medications and the irritant dermatitis induced by RA inconvenience patients." | 7.79 | Silicone sheet containing all-trans retinoic acid and hydroquinone for the treatment of epidermal melanosis. ( Harii, K; Iida, S; Kurita, M; Ohura, N; Sato, S; Takushima, A, 2013) |
| "Melasma is a common disorder affecting a significant percentage of the population, particularly those with skin of color." | 6.74 | A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( Bhawan, J; Byers, HR; Colón, LE; Gottschalk, R; Grimes, P; Guevara, IL; Johnson, LA; Keady, M; Pandya, AG, 2009) |
| "Melasma is a common hyperpigmented skin condition that occurs on the face and other areas prone to light exposure, seriously affecting people's quality of life." | 5.91 | Hydroquinone cream-based polymer microneedle roller for the combined treatment of large-area chloasma. ( Chen, BZ; Cui, Y; Guo, XD; Hao, YY; He, YT; Yu, RX; Zhang, C, 2023) |
| " The principal adverse effects of its chronic use are confetti-like depigmentation and exogenous ochronosis." | 5.35 | Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. ( Azulay-Abulafia, L; Barcaui, CB; Charlín, R; Kac, BK; Rabello-Fonseca, R; Soares, DB, 2008) |
| "To observe and analyze the efficacy of tranexamic acid combined with reduced glutathione in chloasma treatment." | 5.27 | Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma. ( Feng, C; Yan, M, 2018) |
| "To evaluate the use of a nonablative, fractional, 1,927-nm diode laser with and without topical 2% hydroquinone (HQ) cream for moderate-to-severe facial hyperpigmentation in Fitzpatrick skin Types III-V." | 5.27 | The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types. ( Bolton, J; Fabi, SG; Jones, IT; Larsen, L; Vanaman Wilson, MJ, 2018) |
| "To evaluate the erythema and pigmentation of melasma lesions and the surrounding areas in patients receiving triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) regimens." | 5.19 | Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination. ( Fernandes, JD; Hexsel, D; Siega, C; Soirefmann, M, 2014) |
| "Hydroquinone is superior to tretinoin as a priming agent in maintaining the results achieved with peels and in decreasing the incidence of postpeel reactive hyperpigmentation." | 5.11 | Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. ( Grover, C; Nanda, S; Reddy, BS, 2004) |
| "Determine the efficacy and tolerability of a topical, non-hydroquinone, non-retinol pigment-correcting serum (LYT2) for the treatment of pregnancy-induced melasma." | 4.12 | Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum. ( Jiang, LI; Makino, ET; Mehta, RC; Mikati, M; Stephens, TJ, 2022) |
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 3.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| " Three cases of suspected hydroquinone-induced exogenous ochronosis while treating melasma were subjected to dermatoscopy and histopathology studies." | 3.79 | Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. ( Deshpande, DJ; Dhurat, RS; Mishra, SN; Nayak, CS, 2013) |
| "Although bleaching treatment using all-trans retinoic acid (RA) and hydroquinone (HQ) improves epidermal melanosis, the application of two medications and the irritant dermatitis induced by RA inconvenience patients." | 3.79 | Silicone sheet containing all-trans retinoic acid and hydroquinone for the treatment of epidermal melanosis. ( Harii, K; Iida, S; Kurita, M; Ohura, N; Sato, S; Takushima, A, 2013) |
| "A 55-year-old woman with melasma develops biopsy-proved exogenous ochronosis in the setting of prolonged topical hydroquinone use." | 3.74 | Exogenous ochronosis. ( Brown, L; Meehan, S; Merola, JF; Walters, RF, 2008) |
| "Hydroquinone has been successfully used to treat hyperpigmentation disorders for many years." | 3.72 | Lustra, Lustra-AF and Alustra. ( Gupta, AK; Ryder, JE, 2003) |
| " The hydroquinone 4% cohort experienced 5 adverse events, while there were no adverse events associated with the novel topical product." | 3.30 | A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. ( Bajaj, S; Bell, M; Fabi, S; Geronemus, R; Robinson, D; Wang, J; Widgerow, A, 2023) |
| " Original studies that reported pre- and post-treatment Melasma Area Severity Index (MASI)/modified Melasma Area Severity Index (mMASI) scores and/or adverse effects (AEs) were eligible for inclusion." | 3.01 | Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis. ( Aljabban, A; Bain, PA; Bay, CP; Chang, YF; Chung, HJ; Desai, SR; Lee, TL; Oyerinde, O, 2023) |
| "Tranexamic acid (TXA) is a plasmin inhibitor used off-label in the treatment of melasma." | 3.01 | Tranexamic acid in melasma: A focused review on drug administration routes. ( Balazic, E; Jaller, JA; Khanna, U; Kobets, K; Konisky, H, 2023) |
| "Hydroquinone cream was generally better tolerated that cysteamine cream." | 3.01 | Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial. ( Chung, IY; Gourani-Tehrani, S; Honigman, A; Nguyen, J; Paul, E; Remyn, L; Rodrigues, M; Wong, C; Wutami, I, 2021) |
| "Melasma is a common acquired pigmentary disorder characterized by symmetric hyperpigmented macules on the face." | 2.94 | Topical metformin in the treatment of melasma: A preliminary clinical trial. ( Andanooru Chandrappa, NK; Banavase Channakeshavaiah, R, 2020) |
| "Melasma is a common pigmentary disorder for which oral tranexamic acid has shown some efficacy in previous studies." | 2.94 | Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. ( Agustin, T; Legiawati, L; Pandya, AG; Prihartono, J; Shihab, N; Tovar-Garza, A, 2020) |
| "Melasma is a pigmentary disorder affecting mainly face ." | 2.94 | Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma. ( Jawade, S; Kulkarni, S; Madke, B; Sahu, PJ; Saoji, V; Singh, AL, 2020) |
| "Melasma is a common disorder of hyperpigmentation that disproportionately affects individuals with skin of color." | 2.94 | Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma. ( Alexis, AF; Kaufman, BP, 2020) |
| "The management of melasma is still challenging, and new treatment modalities with favorable side effect profile are required." | 2.94 | The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial. ( Dadkhahfar, S; Gheisari, M; Moghimi, HR; Najar Nobari, N; Niknejad, N; Olamaei, E, 2020) |
| "Hydroquinone is the basic treatment that its effect alone and in combination with other medications has been proven." | 2.90 | Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma. ( Banihashemi, M; Dorri, M; Golnouri, F; Jaafari, MR; Marhamati, H; Salehi, M; Taghavi, F; Zabolinejad, N, 2019) |
| "Melasma is a pigmentary disorder characterized by hyperpigmented patchy skin in sun-exposed areas, especially the face." | 2.90 | Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. ( Arrowitz, C; Jiang, LI; Kolbe, L; Mann, T; Schoelermann, AM; Weber, T, 2019) |
| "Tranexamic acid (TA) is a relatively new brightening agent that interferes with keratinocyte-melanocyte interactions." | 2.87 | Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. ( Darayesh, M; Heiran, A; Saki, N, 2018) |
| " No serious adverse events were reported." | 2.84 | Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial. ( Choi, YJ; Kim, BJ; Kim, JY; Kim, WS; Ko, EJ; Min, JH; Nam, JH; Park, KY, 2017) |
| "Melasma's high prevalence and profound psychological impact on patients necessitate efficacious, economical, and safe therapeutic interventions." | 2.84 | Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor ( Abedini, R; Akbari, Z; Ghayoumi, A; Goodarzi, A; Hedayat, K; Hosseini, H; Lajevardi, V, 2017) |
| "Melasma is an abnormal acquired hyperpigmentation of the face of unknown origin, it is considered a single disease and very little has been found regarding its pathogenesis." | 2.82 | Raman spectroscopy analysis of the skin of patients with melasma before standard treatment with topical corticosteroids, retinoic acid, and hydroquinone mixture. ( Arenas, E; Castillo-Martínez, C; González, FJ; León-Bejarano, F; Moncada, B; Ramírez-Elías, MG, 2016) |
| "Melasma is a common acquired skin disorder." | 2.82 | Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma. ( Eshghi, G; Esna Ashari, F; Khezrian, L, 2016) |
| "Melasma is acquired symmetric hypermelanosis characterized by light-to-deep brown pigmentation over cheeks, forehead, upper lip, and nose." | 2.82 | Comparative Evaluation of Efficacy and Tolerability of Glycolic Acid, Salicylic Mandelic Acid, and Phytic Acid Combination Peels in Melasma. ( Bansal, S; Garg, V; Gupta, C; Sarkar, R; Sethi, S, 2016) |
| "Treatment of melasma is unsatisfactory most of the times." | 2.80 | The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. ( Adalatkhah, H; Sadeghi-Bazargani, H, 2015) |
| "Melasma is one of the most common cosmetic disorders with skin darkening." | 2.80 | Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. ( Banihashemi, M; Jaafari, MR; Jabari, A; Salehi, M; Zabolinejad, N, 2015) |
| "1%) reported adverse effects." | 2.80 | Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. ( Dang, Y; Gong, Z; Lai, W; Li, L; Liu, L; Wang, X; Yang, Q; Zhao, G; Zheng, M; Zou, Y, 2015) |
| "Melasma is a common melanosis often difficult to treat." | 2.79 | Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream. ( Bencini, PL; Galimberti, MG; Pellacani, G; Tourlaki, A, 2014) |
| " Adverse events were noted on every visit." | 2.79 | A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. ( Handog, EB; Mendoza, CG; Singzon, IA, 2014) |
| "Together these products offer not only treatment of melasma but also a complete skin care regimen." | 2.78 | Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%. ( Grimes, P; Watson, J, 2013) |
| " Melasma is an irregular brown or grayish-brown symmetric facial hypermelanosis, often affecting women, especially those living in areas with intense ultraviolet radiation." | 2.76 | Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. ( Farshi, S, 2011) |
| "Melasma is common among females." | 2.76 | Instrumental analysis of the pattern of improvement and that of recurrence of melasma in Thai females treated with Kligman-Willis triple combination therapy: confirmation by using its two different formulae. ( Pratchyapruit, W; Sindhavananda, J; Tagami, H; Vashrangsi, N, 2011) |
| "Melasma is a frequent skin disorder characterized by the appearance of abnormal pigment (melanin) deposits in different layers of the skin." | 2.75 | Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study. ( Ardigo, M; Berardesca, E; Cameli, N; Gonzalez, S, 2010) |
| "QS-Nd:YAG laser treatment for melasma in Asians produced only temporary improvement and had side effects." | 2.75 | Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. ( Eimpunth, S; Mornchan, R; Wattanakrai, P, 2010) |
| "Melasma is a common disorder affecting a significant percentage of the population, particularly those with skin of color." | 2.74 | A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( Bhawan, J; Byers, HR; Colón, LE; Gottschalk, R; Grimes, P; Guevara, IL; Johnson, LA; Keady, M; Pandya, AG, 2009) |
| "Melasma is a common disorder of facial hyperpigmentation that can be resistant to treatment." | 2.74 | Melasma: treatment evaluation. ( Amer, A; Gamil, H; Harras, M; Ramadan, A; Salem, A, 2009) |
| " Safety was assessed through the reporting of adverse events." | 2.73 | A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. ( Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008) |
| "Melasma is a common hyperpigmentation disorder that is frequently recalcitrant to treatment." | 2.72 | Community-based trial of a triple-combination agent for the treatment of facial melasma. ( Grimes, P; Kelly, AP; Torok, H; Willis, I, 2006) |
| "Glycolic acid has been added to hydroquinone formulations in the past to enhance their depigmentation effects, but may cause irritation, leading to postinflammatory hyperpigmentation." | 2.71 | Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. ( Guevara, IL; Pandya, AG, 2003) |
| "Melasma is an acquired treatment-resistant hyperpigmentation of the skin." | 2.71 | A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. ( Castanedo-Cazares, JP; Espinal-Perez, LE; Moncada, B, 2004) |
| " only 3 patients (1%) withdrew from the study due to treatment-related adverse events (AEs)." | 2.71 | Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. ( Jones, T; Rich, P; Smith, S; Torok, HM; Tschen, E, 2005) |
| "Melasma is a common problem in Asians, but treatments have not been satisfactory." | 2.69 | Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. ( Chun, SC; Kang, WH; Lee, S, 1998) |
| "Melasma is difficult to clear." | 2.69 | Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. ( Lim, JT, 1999) |
| "Melasma is a common disorder of macular hyperpigmentation which involves mostly in sun exposed areas of the face and neck." | 2.69 | Melasma. ( Kauh, YC; Zachian, TF, 1999) |
| "Melasma is a common disorder of facial hyperpigmentation among Asian women." | 2.68 | Glycolic acid peels in the treatment of melasma among Asian women. ( Lim, JT; Tham, SN, 1997) |
| "Melasma is a circumscribed brown macular hypermelanosis of the areas of the face and neck that are exposed to light." | 2.66 | Usefulness of retinoic acid in the treatment of melasma. ( Fitzpatrick, TB; Kraus, EW; Pathak, MA, 1986) |
| "Melasma is a macular hypermelanosis of the sun-exposed areas of the face and neck." | 2.66 | Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. ( Garcia-Lopez, M; Graupe, K; Lopez-Villafuerte, L; Verallo, V; Verallo-Rowell, VM, 1989) |
| "With proper treatment, melasma can be controlled, improved, and maintained; alternatively, PIH can be cured in most cases." | 2.53 | Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion. ( Emer, J; Prado, G; Sofen, B, 2016) |
| "Melasma is a commonly acquired hypermelanosis that affects sun-exposed areas of the skin, with frequent facial involvement." | 2.53 | Heterogeneous Pathology of Melasma and Its Clinical Implications. ( Hwang, YJ; Kwon, SH; Lee, SK; Park, KC, 2016) |
| "Melasma is a common acquired disorder of pigmentation most commonly seen in those with skin of colour." | 2.52 | Melasma: clinical diagnosis and management options. ( Pandya, AG; Rodrigues, M, 2015) |
| "Melasma is a complex multifactorial disorder whose pathogenesis is not well understood." | 2.48 | Treatment of melasma and the use of intense pulsed light: a review. ( Fabi, S; Goldman, MP; Zaleski, L, 2012) |
| "Melasma is a common, acquired facial skin disorder, mostly involving sun-exposed areas like cheeks, forehead and upper lip." | 2.47 | Melasma--updated treatments. ( Bolanca, Z; Kolić, M; Ljubicić, I; Misanović, B; Situm, M, 2011) |
| "Care must be taken when treating melasma to avoid inducing post-inflammatory hyperpigmentation and ochronosis." | 2.45 | Melasma in Latin America: options for therapy and treatment algorithm. ( Arellano, I; Cestari, T; Hexsel, D; Ortonne, JP, 2009) |
| "Melasma is a common disorder of hyperpigmentation and generally involves areas of the face and neck." | 2.43 | A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. ( Torok, HM, 2006) |
| "Melasma is an irregular brown or grayish-brown facial hypermelanosis, often affecting women, especially those living in areas of intense UV radiation." | 2.43 | The treatment of melasma: a review of clinical trials. ( Gover, MD; Gupta, AK; Nouri, K; Taylor, S, 2006) |
| "Melasma is a common acquired symmetric hypermelanosis characterized by irregular light- to gray-brown macules and patches involving sun-exposed areas of skin." | 2.39 | Melasma. Etiologic and therapeutic considerations. ( Grimes, PE, 1995) |
| " While many pharmaceutical (topical or systemic) or procedural (lasers/chemical peels) options are available, some treatments are not safe/tolerable for long-term use or can induce/exacerbate PIH." | 1.91 | Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation. ( Abidi, Z; Arruda, S; Pannu, S; Sadick, N, 2023) |
| "The aim of this study was to assess the effectiveness of photo rejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation." | 1.91 | Efficacy of photorejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation. ( Lin, C; Zhu, X, 2023) |
| "The search for new compounds for the treatment of melasma without side effects is constant." | 1.91 | Analysis of the antimelanogenic activity of zinc and selenium in vitro. ( da Silva, ACC; de Souza da Costa, N; Galiciolli, MEA; Irioda, AC; Oliveira, CS; Ribeiro, MM; Souza, JV, 2023) |
| "Melasma is a common hyperpigmented skin condition that occurs on the face and other areas prone to light exposure, seriously affecting people's quality of life." | 1.91 | Hydroquinone cream-based polymer microneedle roller for the combined treatment of large-area chloasma. ( Chen, BZ; Cui, Y; Guo, XD; Hao, YY; He, YT; Yu, RX; Zhang, C, 2023) |
| "Melasma is a common acquired circumscribed hyper-pigmentary disorder involving sun-exposed areas, particularly face." | 1.72 | Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: A split-face comparative study. ( Belgaumkar, VA; Tekam, PS, 2022) |
| "Melasma is an acquired disorder of facial pigmentation which is a treatment challenge." | 1.56 | Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years. ( Spierings, NMK, 2020) |
| "Melasma is a highly prevalent hyperpigmentation disorder with a high relapsing rate and a negative impact on the psychological state of the affected patients." | 1.51 | Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. ( Gamal, N; Ibrahim, AM; Nofal, A; Nofal, E; Osman, S, 2019) |
| "Melasma is an acquired, facial hyperpigmentation without a specific origin." | 1.51 | Detection of hydroquinone by Raman spectroscopy in patients with melasma before and after treatment. ( Cabrera-Alonso, R; González, FJ; Guevara, E; Moncada, B; Ramírez-Elías, MG, 2019) |
| "Mefenamic acid was used as an internal standard (I." | 1.51 | A New HPLC-DAD Method for the Concurrent Determination of Hydroquinone, Hydrocortisone Acetate and Tretinoin in Different Pharmaceuticals for Melasma Treatment. ( El-Deen, AK; Ibrahim, F; Sharaf El-Din, MK; Shimizu, K, 2019) |
| "In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C)." | 1.36 | Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. ( Bhawan, J; Colón, LE; Gottschalk, RW; Grimes, PE; Guevara, IL; Johnson, LA; Pandya, AG, 2010) |
| " The principal adverse effects of its chronic use are confetti-like depigmentation and exogenous ochronosis." | 1.35 | Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. ( Azulay-Abulafia, L; Barcaui, CB; Charlín, R; Kac, BK; Rabello-Fonseca, R; Soares, DB, 2008) |
| "A classification of melasma is based on Wood's light examination, classifying it in four major clinical types and patterns: epidermal, dermal, mixed, and indeterminate." | 1.34 | Therapeutical approaches in melasma. ( Buggiani, G; Lotti, T; Ortonne, JP; Prignano, F, 2007) |
| "Melasma is a common disorder of hyperpigmentation typically characterized by relatively symmetric brown or gray-brown patches on sun-exposed facial areas." | 1.34 | An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. ( Grimes, PE, 2007) |
| "Cutaneous pseudolymphoma is an aggregate of mature or abnormal looking lymphocytes in the dermis, which clinically and /or histologically simulates lymphoma but has a benign course and outcome." | 1.33 | Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. ( Dar, NR; Mustafvi, SA; Raza, N, 2005) |
| "The kojic acid preparation was more irritating." | 1.29 | The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. ( Fulton, JE; Garcia, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (3.76) | 18.7374 |
| 1990's | 9 (6.77) | 18.2507 |
| 2000's | 34 (25.56) | 29.6817 |
| 2010's | 60 (45.11) | 24.3611 |
| 2020's | 25 (18.80) | 2.80 |
| Authors | Studies |
|---|---|
| Makino, ET | 1 |
| Jiang, LI | 2 |
| Stephens, TJ | 1 |
| Mikati, M | 1 |
| Mehta, RC | 1 |
| Tekam, PS | 1 |
| Belgaumkar, VA | 1 |
| Manuskiatti, W | 1 |
| Yan, C | 1 |
| Gulfan, MCB | 1 |
| Techapichetvanich, T | 1 |
| Wanitphakdeedecha, R | 1 |
| Wattanakrai, P | 3 |
| Nimmannitya, K | 2 |
| Chang, YF | 1 |
| Lee, TL | 1 |
| Oyerinde, O | 1 |
| Desai, SR | 1 |
| Aljabban, A | 1 |
| Bay, CP | 1 |
| Bain, PA | 1 |
| Chung, HJ | 1 |
| Konisky, H | 1 |
| Balazic, E | 1 |
| Jaller, JA | 1 |
| Khanna, U | 1 |
| Kobets, K | 1 |
| He, YT | 1 |
| Hao, YY | 1 |
| Yu, RX | 1 |
| Zhang, C | 1 |
| Chen, BZ | 1 |
| Cui, Y | 1 |
| Guo, XD | 1 |
| Wang, J | 1 |
| Fabi, S | 2 |
| Robinson, D | 1 |
| Bajaj, S | 1 |
| Geronemus, R | 1 |
| Bell, M | 1 |
| Widgerow, A | 1 |
| Yousefi, M | 1 |
| Hadian, K | 1 |
| Babossalam, S | 1 |
| Diab, R | 1 |
| Akhlaghi, M | 1 |
| Aghighi, M | 1 |
| Abdollahimajd, F | 1 |
| Shokri, B | 1 |
| da Silva, ACC | 1 |
| Ribeiro, MM | 1 |
| de Souza da Costa, N | 1 |
| Galiciolli, MEA | 1 |
| Souza, JV | 1 |
| Irioda, AC | 1 |
| Oliveira, CS | 1 |
| Lin, C | 1 |
| Zhu, X | 1 |
| Sadick, N | 1 |
| Pannu, S | 1 |
| Abidi, Z | 1 |
| Arruda, S | 1 |
| Wang, YJ | 1 |
| Lin, ET | 1 |
| Chen, YT | 1 |
| Chiu, PC | 1 |
| Lin, BS | 1 |
| Chiang, HM | 1 |
| Huang, YH | 1 |
| Wang, KY | 1 |
| Lin, HY | 1 |
| Chang, TM | 1 |
| Chang, CC | 1 |
| Banavase Channakeshavaiah, R | 1 |
| Andanooru Chandrappa, NK | 1 |
| Spierings, NMK | 1 |
| Bronzina, E | 1 |
| Clement, A | 1 |
| Marie, B | 1 |
| Fook Chong, KT | 1 |
| Faure, P | 1 |
| Passeron, T | 3 |
| Ma, Y | 1 |
| Millette, D | 1 |
| Nalluri, R | 1 |
| Yoo, J | 1 |
| Shihab, N | 1 |
| Prihartono, J | 1 |
| Tovar-Garza, A | 1 |
| Agustin, T | 1 |
| Legiawati, L | 1 |
| Pandya, AG | 8 |
| Arreola Jauregui, IE | 1 |
| Huerta Rivera, G | 1 |
| Soria Orozco, M | 1 |
| Meyer-Nava, S | 1 |
| Paniagua Santos, JE | 1 |
| López Zaldo, JB | 1 |
| Meyer-Nava, I | 1 |
| Madrid Carrillo, C | 1 |
| Zaldo Rolón, IE | 1 |
| Baeza Echeverría, AE | 1 |
| Vázquez Huerta, M | 1 |
| Ramírez-Oliveros, JF | 1 |
| de Abreu, L | 1 |
| Tamler, C | 1 |
| Vilhena, P | 1 |
| de Barros, MH | 1 |
| Mohamed, EM | 1 |
| Younes, AH | 1 |
| Hussein, GM | 1 |
| Sahu, PJ | 1 |
| Singh, AL | 1 |
| Kulkarni, S | 1 |
| Madke, B | 1 |
| Saoji, V | 1 |
| Jawade, S | 1 |
| Nguyen, J | 1 |
| Remyn, L | 1 |
| Chung, IY | 1 |
| Honigman, A | 1 |
| Gourani-Tehrani, S | 1 |
| Wutami, I | 1 |
| Wong, C | 1 |
| Paul, E | 1 |
| Rodrigues, M | 2 |
| Kaufman, BP | 1 |
| Alexis, AF | 1 |
| Choi, YJ | 1 |
| Nam, JH | 1 |
| Kim, JY | 1 |
| Min, JH | 1 |
| Park, KY | 1 |
| Ko, EJ | 1 |
| Kim, BJ | 1 |
| Kim, WS | 2 |
| Chalermchai, T | 1 |
| Rummaneethorn, P | 1 |
| Saki, N | 1 |
| Darayesh, M | 1 |
| Heiran, A | 1 |
| Vanaman Wilson, MJ | 1 |
| Jones, IT | 1 |
| Bolton, J | 1 |
| Larsen, L | 1 |
| Fabi, SG | 2 |
| Cabrera-Alonso, R | 1 |
| Guevara, E | 1 |
| Ramírez-Elías, MG | 2 |
| Moncada, B | 3 |
| González, FJ | 2 |
| Taghavi, F | 1 |
| Banihashemi, M | 2 |
| Zabolinejad, N | 2 |
| Salehi, M | 2 |
| Jaafari, MR | 2 |
| Marhamati, H | 1 |
| Golnouri, F | 1 |
| Dorri, M | 1 |
| Nofal, A | 1 |
| Ibrahim, AM | 1 |
| Nofal, E | 1 |
| Gamal, N | 1 |
| Osman, S | 1 |
| Feng, C | 1 |
| Yan, M | 1 |
| Arrowitz, C | 1 |
| Schoelermann, AM | 1 |
| Mann, T | 1 |
| Weber, T | 1 |
| Kolbe, L | 1 |
| Zubair, R | 1 |
| Lyons, AB | 1 |
| Vellaichamy, G | 1 |
| Peacock, A | 1 |
| Hamzavi, I | 1 |
| Pekmezci, E | 1 |
| Ibrahim, F | 1 |
| Sharaf El-Din, MK | 1 |
| El-Deen, AK | 1 |
| Shimizu, K | 1 |
| Gheisari, M | 1 |
| Dadkhahfar, S | 1 |
| Olamaei, E | 1 |
| Moghimi, HR | 1 |
| Niknejad, N | 1 |
| Najar Nobari, N | 1 |
| Dreher, F | 2 |
| Draelos, ZD | 1 |
| Gold, MH | 2 |
| Goldman, MP | 3 |
| Puissegur Lupo, ML | 1 |
| Grimes, P | 3 |
| Watson, J | 1 |
| Monheit, GD | 1 |
| Iida, S | 1 |
| Takushima, A | 1 |
| Ohura, N | 1 |
| Sato, S | 1 |
| Kurita, M | 1 |
| Harii, K | 1 |
| Chaudhary, S | 1 |
| Dayal, S | 1 |
| Thornfeldt, C | 1 |
| Rizer, RL | 1 |
| Trookman, NS | 1 |
| Liu, WC | 1 |
| Tey, HL | 1 |
| Lee, JS | 1 |
| Goh, BK | 1 |
| Hexsel, D | 4 |
| Soirefmann, M | 1 |
| Fernandes, JD | 1 |
| Siega, C | 1 |
| Hsieh, PW | 2 |
| Aljuffali, IA | 1 |
| Fang, CL | 1 |
| Chang, SH | 1 |
| Fang, JY | 2 |
| Mendoza, CG | 1 |
| Singzon, IA | 1 |
| Handog, EB | 1 |
| Hammami Ghorbel, H | 1 |
| Boukari, F | 1 |
| Fontas, E | 2 |
| Montaudié, H | 1 |
| Bahadoran, P | 2 |
| Lacour, JP | 2 |
| Ibrahim, ZA | 1 |
| Gheida, SF | 1 |
| El Maghraby, GM | 1 |
| Farag, ZE | 1 |
| Gong, Z | 1 |
| Lai, W | 1 |
| Zhao, G | 1 |
| Wang, X | 1 |
| Zheng, M | 1 |
| Li, L | 1 |
| Yang, Q | 1 |
| Dang, Y | 1 |
| Liu, L | 1 |
| Zou, Y | 1 |
| Jabari, A | 1 |
| Castillo-Martínez, C | 1 |
| Arenas, E | 1 |
| León-Bejarano, F | 1 |
| Adalatkhah, H | 1 |
| Sadeghi-Bazargani, H | 1 |
| Eshghi, G | 1 |
| Khezrian, L | 1 |
| Esna Ashari, F | 1 |
| Sarkar, R | 3 |
| Garg, V | 1 |
| Bansal, S | 1 |
| Sethi, S | 1 |
| Gupta, C | 1 |
| Rendon, M | 2 |
| Dryer, L | 1 |
| Sofen, B | 1 |
| Prado, G | 1 |
| Emer, J | 1 |
| Kwon, SH | 1 |
| Hwang, YJ | 1 |
| Lee, SK | 1 |
| Park, KC | 2 |
| Kwon, HH | 1 |
| Ohn, J | 1 |
| Suh, DH | 1 |
| Park, HY | 1 |
| Choi, SC | 1 |
| Jung, JY | 1 |
| Kwon, IH | 1 |
| Park, GH | 1 |
| Lajevardi, V | 1 |
| Ghayoumi, A | 1 |
| Abedini, R | 1 |
| Hosseini, H | 1 |
| Goodarzi, A | 1 |
| Akbari, Z | 1 |
| Hedayat, K | 1 |
| Rendon, MI | 1 |
| Barkovic, S | 1 |
| Córdova, ME | 1 |
| Pérez-Rojas, DO | 1 |
| López-Marquet, AD | 1 |
| Arenas, R | 1 |
| Hung, CF | 1 |
| Lin, CH | 1 |
| Huang, CW | 1 |
| Chan, R | 1 |
| Lee, MH | 1 |
| Lee, ES | 1 |
| Chang, SE | 1 |
| Leow, YH | 1 |
| Tay, YK | 1 |
| Legarda-Montinola, F | 1 |
| Tsai, RY | 1 |
| Tsai, TH | 1 |
| Shek, S | 1 |
| Kerrouche, N | 1 |
| Thomas, G | 1 |
| Verallo-Rowell, V | 1 |
| Merola, JF | 1 |
| Meehan, S | 1 |
| Walters, RF | 1 |
| Brown, L | 1 |
| Cardona, LM | 1 |
| Bussear, EW | 1 |
| Benitez, AL | 1 |
| Colón, LE | 4 |
| Johnson, LA | 4 |
| Salem, A | 1 |
| Gamil, H | 1 |
| Ramadan, A | 1 |
| Harras, M | 1 |
| Amer, A | 1 |
| Grimes, PE | 5 |
| Cestari, T | 3 |
| Arellano, I | 2 |
| Ortonne, JP | 3 |
| Bhawan, J | 2 |
| Keady, M | 1 |
| Byers, HR | 1 |
| Guevara, IL | 6 |
| Gottschalk, R | 1 |
| Alikhan, A | 1 |
| Daly, M | 1 |
| Wu, J | 1 |
| Balkrishnan, R | 1 |
| Feldman, SR | 3 |
| Werlinger, KD | 1 |
| Mornchan, R | 1 |
| Eimpunth, S | 1 |
| Ardigo, M | 1 |
| Cameli, N | 1 |
| Berardesca, E | 1 |
| Gonzalez, S | 1 |
| Jeong, SY | 1 |
| Shin, JB | 1 |
| Yeo, UC | 1 |
| Kim, IH | 1 |
| Gottschalk, RW | 2 |
| Zawar, V | 1 |
| Chuh, A | 1 |
| Kodali, S | 1 |
| Carrigan, CR | 1 |
| Daulat, S | 1 |
| Blanco, G | 1 |
| Boker, A | 1 |
| Hynan, LS | 1 |
| Kroon, MW | 1 |
| Wind, BS | 1 |
| Beek, JF | 1 |
| van der Veen, JP | 1 |
| Nieuweboer-Krobotová, L | 1 |
| Bos, JD | 1 |
| Wolkerstorfer, A | 1 |
| Pratchyapruit, W | 1 |
| Vashrangsi, N | 1 |
| Sindhavananda, J | 1 |
| Tagami, H | 1 |
| Palm, MD | 1 |
| Preston, N | 1 |
| Godse, KV | 1 |
| Sakhia, J | 1 |
| Ocampo-Candiani, J | 1 |
| Azulay-Abulafia, L | 2 |
| Bezerra Trindade Neto, P | 1 |
| Machado-Pinto, J | 1 |
| Muñoz, H | 1 |
| Rivitti-Machado, MC | 1 |
| Sittart, JA | 1 |
| Trindade de Almeida, AR | 1 |
| Rego, V | 1 |
| Paliargues, F | 1 |
| Marques-Hassun, K | 1 |
| Rossi, AM | 1 |
| Perez, MI | 1 |
| Kang, HY | 1 |
| Farshi, S | 1 |
| Situm, M | 1 |
| Kolić, M | 1 |
| Bolanca, Z | 1 |
| Ljubicić, I | 1 |
| Misanović, B | 1 |
| Kauvar, AN | 1 |
| Mishra, SN | 1 |
| Dhurat, RS | 1 |
| Deshpande, DJ | 1 |
| Nayak, CS | 1 |
| Tourlaki, A | 1 |
| Galimberti, MG | 1 |
| Pellacani, G | 1 |
| Bencini, PL | 1 |
| Zaleski, L | 1 |
| Kaur, C | 1 |
| Bhalla, M | 1 |
| Kanwar, AJ | 1 |
| Haddad, AL | 1 |
| Matos, LF | 1 |
| Brunstein, F | 1 |
| Ferreira, LM | 1 |
| Silva, A | 1 |
| Costa, D | 1 |
| Gupta, AK | 2 |
| Ryder, JE | 1 |
| ZAMITH, VA | 1 |
| FISHER, AA | 1 |
| Nanda, S | 1 |
| Grover, C | 1 |
| Reddy, BS | 1 |
| Espinal-Perez, LE | 1 |
| Castanedo-Cazares, JP | 1 |
| Cayce, KA | 1 |
| McMichael, AJ | 1 |
| Torok, HM | 2 |
| Jones, T | 1 |
| Rich, P | 1 |
| Smith, S | 1 |
| Tschen, E | 1 |
| Astaneh, R | 1 |
| Farboud, E | 1 |
| Nazemi, MJ | 1 |
| Dar, NR | 1 |
| Mustafvi, SA | 1 |
| Raza, N | 1 |
| Kelly, AP | 1 |
| Torok, H | 1 |
| Willis, I | 1 |
| Yoshimura, K | 1 |
| Sato, K | 1 |
| Aiba-Kojima, E | 1 |
| Matsumoto, D | 1 |
| Machino, C | 1 |
| Nagase, T | 1 |
| Gonda, K | 1 |
| Koshima, I | 1 |
| Stanfield, JW | 1 |
| Levitt, J | 1 |
| Lynde, CB | 1 |
| Kraft, JN | 1 |
| Lynde, CW | 1 |
| Gover, MD | 1 |
| Nouri, K | 1 |
| Taylor, S | 1 |
| Cestari, TF | 1 |
| Viegas, ML | 1 |
| Azulay, L | 1 |
| Hassun, K | 2 |
| Almeida, AR | 1 |
| Rêgo, VR | 1 |
| Mendes, AM | 1 |
| Filho, JW | 1 |
| Junqueira, H | 1 |
| Ferreira Cestari, T | 1 |
| Sittart, A | 1 |
| de Lourdes Viegas, M | 1 |
| Adjadj, L | 1 |
| Hux, M | 1 |
| Shimizu, MR | 1 |
| Rives, VP | 1 |
| Prignano, F | 1 |
| Buggiani, G | 1 |
| Lotti, T | 1 |
| Picardo, M | 1 |
| Carrera, M | 1 |
| Charlín, R | 1 |
| Barcaui, CB | 1 |
| Kac, BK | 1 |
| Soares, DB | 1 |
| Rabello-Fonseca, R | 1 |
| Garg, VK | 1 |
| Agarwal, R | 1 |
| Tan, SK | 1 |
| Sim, CS | 1 |
| Goh, CL | 1 |
| Yi, K | 1 |
| Hart, LL | 1 |
| Menke, HE | 1 |
| Westerhof, W | 1 |
| Garcia, A | 1 |
| Fulton, JE | 1 |
| Lim, JT | 2 |
| Tham, SN | 1 |
| Kang, WH | 1 |
| Chun, SC | 1 |
| Lee, S | 1 |
| Kimura, T | 1 |
| Doi, K | 1 |
| Kauh, YC | 1 |
| Zachian, TF | 1 |
| Verallo-Rowell, VM | 1 |
| Verallo, V | 1 |
| Graupe, K | 1 |
| Lopez-Villafuerte, L | 1 |
| Garcia-Lopez, M | 1 |
| Melli, MC | 1 |
| Pathak, MA | 1 |
| Fitzpatrick, TB | 1 |
| Kraus, EW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial[NCT04597203] | 20 participants (Anticipated) | Interventional | 2020-10-31 | Recruiting | |||
| Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation: A Randomized Control, Double Blinded-trial[NCT05206318] | 40 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | |||
| OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women[NCT04834167] | 32 participants (Actual) | Interventional | 2021-05-01 | Completed | |||
| Comparing Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment[NCT03899233] | Phase 4 | 25 participants (Anticipated) | Interventional | 2019-04-01 | Not yet recruiting | ||
| Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma[NCT03982849] | Phase 2 | 92 participants (Actual) | Interventional | 2019-07-15 | Completed | ||
| Topical Silymarin Versus Combined Topical Silymarin and Microneedling in Treatment of Melasma: Split Face Study[NCT05099601] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-05-31 | Not yet recruiting | ||
| Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma[NCT01850186] | 20 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma[NCT00469183] | Phase 4 | 70 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study[NCT02812719] | Early Phase 1 | 0 participants (Actual) | Interventional | 2018-07-31 | Withdrawn (stopped due to Study did not receive funding and will not be implemented.) | ||
| Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study[NCT03926845] | 200 participants (Actual) | Interventional | 2019-04-29 | Completed | |||
| Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators[NCT01952379] | 20 participants (Actual) | Observational | 2013-07-31 | Completed | |||
| Double Blind Randomized Study of 2% Miconazol Versus 4% Hydroquinone in the Treatment for Melasma.[NCT01661556] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| A Double Blind Randomized Study Comparing the Ultraviolet (UV) Photoprotection With UV Plus Visible Light Photoprotection in the Treatment of Melasma.[NCT01695356] | Phase 4 | 68 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.[NCT00975312] | Phase 2 | 22 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Efficacy of Combined Peels in Treatment of Melasma Using Modified Jessner's Solution With 20%Trichloroacetic Acid Versus 70%Glycolic Acid With 20% Trichloroacetic Acid : A Split-face Study[NCT03153852] | Phase 4 | 30 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| Evaluation of the Therapeutic Effect of Platelet Rich Plasma in Melasma[NCT03308370] | Phase 3 | 26 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for hydroquinone and Chloasma
| Article | Year |
|---|---|
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
Topics: Cysteamine; Humans; Melanosis; Tranexamic Acid; Treatment Outcome; Zinc Sulfate | 2023 |
Tranexamic acid in melasma: A focused review on drug administration routes.
Topics: Administration, Topical; Adult; Female; Humans; Hydroquinones; Melanosis; Tranexamic Acid; Treatment | 2023 |
What's New in Pigmentary Disorders.
Topics: alpha-MSH; Antifibrinolytic Agents; Bimatoprost; Dermatologic Agents; Humans; Hydroquinones; Inflamm | 2019 |
Melasma: clinical diagnosis and management options.
Topics: Administration, Cutaneous; Antioxidants; Chemexfoliation; Cosmetics; Drug Combinations; Humans; Hydr | 2015 |
Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
Topics: Dermatologic Agents; Humans; Hydroquinones; Hyperpigmentation; Inflammation; Melanosis; Phototherapy | 2016 |
Heterogeneous Pathology of Melasma and Its Clinical Implications.
Topics: Administration, Topical; Antioxidants; Basement Membrane; Chloroquine; Dermis; Disease Management; G | 2016 |
Management of hyperpigmentation in darker racial ethnic groups.
Topics: Antioxidants; Chemexfoliation; Dermabrasion; Humans; Hydroquinones; Hyperpigmentation; Laser Therapy | 2009 |
Melasma in Latin America: options for therapy and treatment algorithm.
Topics: Algorithms; Drug Therapy, Combination; Evidence-Based Medicine; Fluocinolone Acetonide; Humans; Hydr | 2009 |
Melasma--updated treatments.
Topics: Adrenal Cortex Hormones; Female; Humans; Hydroquinones; Keratolytic Agents; Male; Melanosis; Photoch | 2011 |
Treatment of melasma and the use of intense pulsed light: a review.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Dermatologic Agents; Face; Female; Foll | 2012 |
Hyperpigmentation: an overview of the common afflictions.
Topics: Chemexfoliation; Cryotherapy; Dermatologic Agents; Dicarboxylic Acids; Humans; Hydroquinones; Hyperp | 2004 |
A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.
Topics: Administration, Cutaneous; Fluocinolone Acetonide; Glucocorticoids; Humans; Hydroquinones; Keratolyt | 2006 |
Topical treatments for melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Dermatologic Agents; Female; Humans; Hydroquinones; Hyperpigmentation; Infl | 2006 |
The treatment of melasma: a review of clinical trials.
Topics: Adrenal Cortex Hormones; Adult; Chemexfoliation; Clinical Trials as Topic; Combined Modality Therapy | 2006 |
The treatment of melasma: a review of clinical trials.
Topics: Adrenal Cortex Hormones; Adult; Chemexfoliation; Clinical Trials as Topic; Combined Modality Therapy | 2006 |
The treatment of melasma: a review of clinical trials.
Topics: Adrenal Cortex Hormones; Adult; Chemexfoliation; Clinical Trials as Topic; Combined Modality Therapy | 2006 |
The treatment of melasma: a review of clinical trials.
Topics: Adrenal Cortex Hormones; Adult; Chemexfoliation; Clinical Trials as Topic; Combined Modality Therapy | 2006 |
New and experimental treatments of cloasma and other hypermelanoses.
Topics: Chemexfoliation; Dermatologic Agents; Drug Combinations; Flavonoids; Glucocorticoids; Humans; Hydroq | 2007 |
Hydroquinone-induced exogenous ochronosis in Chinese--two case reports and a review.
Topics: Administration, Cutaneous; Asian People; Dermatologic Agents; Female; Humans; Hydroquinones; Melanos | 2008 |
Melasma. Etiologic and therapeutic considerations.
Topics: Administration, Cutaneous; Chemexfoliation; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; | 1995 |
Melasma. Etiologic and therapeutic considerations.
Topics: Administration, Cutaneous; Chemexfoliation; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; | 1995 |
Melasma. Etiologic and therapeutic considerations.
Topics: Administration, Cutaneous; Chemexfoliation; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; | 1995 |
Melasma. Etiologic and therapeutic considerations.
Topics: Administration, Cutaneous; Chemexfoliation; Dermatologic Agents; Dicarboxylic Acids; Female; Humans; | 1995 |
67 trials available for hydroquinone and Chloasma
| Article | Year |
|---|---|
Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
Topics: Humans; Hydroquinones; Lasers, Solid-State; Melanins; Melanosis; Treatment Outcome | 2022 |
A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Topics: Double-Blind Method; Humans; Hydroquinones; Melanosis; Silymarin; Treatment Outcome | 2022 |
A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Topics: Double-Blind Method; Humans; Hydroquinones; Melanosis; Silymarin; Treatment Outcome | 2022 |
A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Topics: Double-Blind Method; Humans; Hydroquinones; Melanosis; Silymarin; Treatment Outcome | 2022 |
A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Topics: Double-Blind Method; Humans; Hydroquinones; Melanosis; Silymarin; Treatment Outcome | 2022 |
A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Hydroquinones; Hyperpigmentation; Melanosis; | 2023 |
Split-face comparison of hydroquinone 4% plus nitrogen plasma vs. hydroquinone 4% alone in the treatment of melasma.
Topics: Female; Humans; Hydroquinones; Melanins; Melanosis; Treatment Outcome | 2023 |
Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma.
Topics: Adult; Asian People; Combined Modality Therapy; Drug Combinations; Female; Fluocinolone Acetonide; H | 2020 |
Topical metformin in the treatment of melasma: A preliminary clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Fluocinolone Acetonide; Humans; Hydroquin | 2020 |
Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.
Topics: Administration, Topical; Adult; Cosmetics; Double-Blind Method; Endothelial Cells; Female; Fibroblas | 2020 |
Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifibrinolytic Agents; Double-Blind Method | 2020 |
Efficacy of 577 nm pro-yellow laser in the treatment of melasma: a prospective split-face study.
Topics: Adolescent; Adult; Combined Modality Therapy; Female; Humans; Hydroquinones; Lasers, Solid-State; Lo | 2020 |
Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Drug Combinations; Female; Fluoc | 2020 |
Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Topics: Administration, Topical; Adult; Cysteamine; Dermatologic Agents; Double-Blind Method; Female; Humans | 2021 |
Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Topics: Adult; Aged; Dermatologic Agents; Face; Female; Humans; Hydroquinones; Male; Melanosis; Middle Aged; | 2020 |
Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Topics: Administration, Cutaneous; Adult; Aged; Combined Modality Therapy; Enzyme Inhibitors; Female; Follow | 2017 |
Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma.
Topics: Adult; Erythema; Female; Humans; Hydroquinones; Lasers, Solid-State; Low-Level Light Therapy; Melano | 2018 |
Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
Topics: Administration, Topical; Adult; Erythema; Face; Female; Humans; Hydroquinones; Melanins; Melanosis; | 2018 |
The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Topics: Administration, Cutaneous; Adult; Aged; Antioxidants; Face; Female; Humans; Hydroquinones; Hyperpigm | 2018 |
Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma.
Topics: Administration, Cutaneous; Adult; Double-Blind Method; Face; Female; Humans; Hydroquinones; Liposome | 2019 |
Clinical observation on tranexamic acid combined with reduced glutathione for the treatment of chloasma.
Topics: Administration, Cutaneous; Adult; Drug Therapy, Combination; Female; Glutathione; Humans; Hydroquino | 2018 |
Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma.
Topics: Administration, Cutaneous; Adult; Aged; Double-Blind Method; Face; Female; Humans; Hydroquinones; Me | 2019 |
The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.
Topics: Adult; Double-Blind Method; Female; Humans; Hydroquinones; Melanosis; Methimazole; Middle Aged; Pati | 2020 |
Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
Topics: Administration, Cutaneous; Antioxidants; Drug Therapy, Combination; Female; Humans; Hydroquinones; K | 2013 |
Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Dermatologic Agents; Drug Combinations; Female; | 2013 |
Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Chemexfoliation; Female; Glycolates; Humans; Hydrocor | 2013 |
Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antioxidants; Drug Therapy, Combination; Erythema; Fluo | 2014 |
A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Hydroquinones; Male; Melanosis; Middle Aged; | 2014 |
Copper Bromide Laser vs Triple-Combination Cream for the Treatment of Melasma: A Randomized Clinical Trial.
Topics: Adult; Bromides; Copper; Dexamethasone; Drug Combinations; Female; Humans; Hydroquinones; Laser Ther | 2015 |
Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Topics: Adolescent; Adult; Asian People; Double-Blind Method; Female; Fluocinolone Acetonide; Humans; Hydroq | 2015 |
Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Topics: Adult; Dermatologic Agents; Double-Blind Method; Female; Humans; Hydroquinones; Liposomes; Melanosis | 2015 |
Raman spectroscopy analysis of the skin of patients with melasma before standard treatment with topical corticosteroids, retinoic acid, and hydroquinone mixture.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Dermatologic Ag | 2016 |
The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
Topics: Administration, Cutaneous; Adult; Double-Blind Method; Female; Flutamide; Humans; Hydroquinones; Ira | 2015 |
Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma.
Topics: Administration, Topical; Adult; Dexamethasone; Female; Humans; Hydroquinones; Melanosis; Middle Aged | 2016 |
Comparative Evaluation of Efficacy and Tolerability of Glycolic Acid, Salicylic Mandelic Acid, and Phytic Acid Combination Peels in Melasma.
Topics: Adult; Antioxidants; Chemexfoliation; Drug Combinations; Female; Follow-Up Studies; Glycolates; Huma | 2016 |
Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a shor
Topics: Administration, Oral; Administration, Topical; Adult; Drug Therapy, Combination; Female; Follow-Up S | 2017 |
A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Asian People; Double-Blind Method; Drug Comb | 2008 |
Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study.
Topics: Administration, Cutaneous; Adult; Chemexfoliation; Dermatologic Agents; Drug Combinations; Drug Ther | 2008 |
Melasma: treatment evaluation.
Topics: Administration, Cutaneous; Caustics; Dermatologic Agents; Egypt; Female; Humans; Hydroquinones; Lase | 2009 |
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
Topics: Administration, Cutaneous; Adult; Atrophy; Dermatologic Agents; Drug Combinations; Female; Fluocinol | 2009 |
Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
Topics: Administration, Topical; Adult; Asian People; Combined Modality Therapy; Dermatologic Agents; Female | 2010 |
Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study.
Topics: Adult; Drug Monitoring; Drug Therapy, Combination; Epidermis; Face; Female; Follow-Up Studies; Human | 2010 |
Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
Topics: Administration, Topical; Adult; Antioxidants; Combined Modality Therapy; Cross-Over Studies; Drug Ad | 2010 |
A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women.
Topics: Adult; Chemexfoliation; Female; Hispanic or Latino; Humans; Hydroquinones; Keratolytic Agents; Melan | 2010 |
Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.
Topics: Administration, Topical; Adult; Female; Humans; Hydroquinones; Laser Therapy; Melanosis; Middle Aged | 2011 |
Instrumental analysis of the pattern of improvement and that of recurrence of melasma in Thai females treated with Kligman-Willis triple combination therapy: confirmation by using its two different formulae.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Asian People; Chemistry, Pharmaceutical; Dr | 2011 |
Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Combined Modality Therapy; Female; Fluocinolone Acetonide; Hu | 2011 |
Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.
Topics: Dermatologic Agents; Drug Therapy, Combination; Fluocinolone Acetonide; Humans; Hydroquinones; Melan | 2012 |
Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study.
Topics: Adult; Bleaching Agents; Dermatologic Agents; Drug Combinations; Female; Fluocinolone Acetonide; Glu | 2011 |
Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.
Topics: Adult; Antioxidants; Dermatologic Agents; Dicarboxylic Acids; Emollients; Female; Humans; Hydroquino | 2011 |
Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers.
Topics: Adult; Antioxidants; Ascorbic Acid; Combined Modality Therapy; Dermabrasion; Female; Follow-Up Studi | 2012 |
Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream.
Topics: Adult; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Hydrocortisone; Hydroquinones | 2014 |
The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study.
Topics: Administration, Topical; Adult; Chemexfoliation; Drug Combinations; Female; Glycolates; Humans; Hydr | 2002 |
A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma.
Topics: Adult; Dermatologic Agents; Double-Blind Method; Drug Eruptions; Humans; Hydroquinones; Melanosis; M | 2003 |
Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
Topics: Administration, Cutaneous; Adult; Ascorbic Acid; Drug Therapy, Combination; Female; Glycolates; Huma | 2003 |
Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma.
Topics: Administration, Topical; Adolescent; Adult; Chemexfoliation; Double-Blind Method; Female; Humans; Hy | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Topics: Administration, Topical; Adult; Ascorbic Acid; Dermatologic Agents; Double-Blind Method; Female; Hum | 2004 |
A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Adult; Dermatologic Agents; Drug Administration Schedule; Drug Combinations | 2004 |
Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
Topics: Antioxidants; Drug Combinations; Facial Dermatoses; Female; Fluocinolone Acetonide; Glucocorticoids; | 2005 |
Community-based trial of a triple-combination agent for the treatment of facial melasma.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Dermato | 2006 |
Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens.
Topics: Administration, Cutaneous; Adult; Chalcones; Cinnamates; Dose-Response Relationship, Drug; Dose-Resp | 2006 |
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
Topics: Administration, Topical; Adult; Drug Combinations; Emollients; Facial Dermatoses; Female; Fluocinolo | 2007 |
Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.
Topics: Administration, Topical; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Fluocinolone Acetonid | 2007 |
Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels.
Topics: Adolescent; Adult; Chemexfoliation; Female; Glycolates; Humans; Hydroquinones; Male; Melanosis; Midd | 2008 |
Glycolic acid peels in the treatment of melasma among Asian women.
Topics: Administration, Topical; Adult; Asian People; Chemexfoliation; China; Drug Combinations; Female; Gly | 1997 |
Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Asian People; Dermis; Drug Administration | 1998 |
Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid.
Topics: Adult; Aspergillus oryzae; Double-Blind Method; Drug Combinations; Facial Dermatoses; Female; Gels; | 1999 |
Melasma.
Topics: Adult; Demography; Female; Humans; Hydroquinones; Keratolytic Agents; Melanosis; Middle Aged; Radiat | 1999 |
Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma.
Topics: Administration, Topical; Dicarboxylic Acids; Double-Blind Method; Drug Eruptions; Female; Humans; Hy | 1989 |
Usefulness of retinoic acid in the treatment of melasma.
Topics: Administration, Topical; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydroquinones; | 1986 |
49 other studies available for hydroquinone and Chloasma
| Article | Year |
|---|---|
Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum.
Topics: Administration, Cutaneous; Adult; Female; Humans; Hydroquinones; Hyperpigmentation; Melanosis; Pregn | 2022 |
Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: A split-face comparative study.
Topics: Humans; Hydroquinones; Melanosis; Platelet-Rich Plasma; Treatment Outcome | 2022 |
Hydroquinone cream-based polymer microneedle roller for the combined treatment of large-area chloasma.
Topics: Animals; Hydroquinones; Melanosis; Mice; Paraffin; Polymers; Quality of Life; Ultraviolet Rays | 2023 |
Analysis of the antimelanogenic activity of zinc and selenium in vitro.
Topics: Humans; Hydroquinones; Melanins; Melanosis; Selenium; Trace Elements; Zinc | 2023 |
Efficacy of photorejuvenation combined with tranexamic acid and hydroquinone cream in the treatment of complex facial pigmentation.
Topics: Humans; Hydroquinones; Melanosis; Pigmentation; Retrospective Studies; Tranexamic Acid; Water | 2023 |
Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Topics: Adult; Female; Humans; Hyperpigmentation; Melanosis; Retinoids; Skin | 2023 |
Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years.
Topics: Administration, Cutaneous; Administration, Oral; Chemexfoliation; Clinical Trials as Topic; Combined | 2020 |
UK-based dermatologist online survey on the current practice and training in the management of melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Alkaptonuria; Dermatologists; Drug Therapy, Combination; Humans; Hydroquino | 2020 |
A cross-sectional report on melasma among Hispanic patients: Evaluating the role of oral tranexamic acid versus oral tranexamic acid plus hydroquinone.
Topics: Administration, Oral; Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Female; Hispani | 2020 |
Microneedling with Drug Delivery (Hydroquinone 4% Serum) as an Adjuvant Therapy for Recalcitrant Melasma.
Topics: Adult; Combined Modality Therapy; Cosmetic Techniques; Dermatologic Agents; Drug Delivery Systems; F | 2020 |
Detection of hydroquinone by Raman spectroscopy in patients with melasma before and after treatment.
Topics: Adult; Drug Monitoring; Drug Therapy, Combination; Female; Fluocinolone Acetonide; Humans; Hydroquin | 2019 |
Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study.
Topics: Administration, Cutaneous; Adult; Antioxidants; Female; Humans; Hydroquinones; Melanosis; Middle Age | 2019 |
Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study.
Topics: Administration, Cutaneous; Adult; Antioxidants; Female; Humans; Hydroquinones; Melanosis; Middle Age | 2019 |
Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study.
Topics: Administration, Cutaneous; Adult; Antioxidants; Female; Humans; Hydroquinones; Melanosis; Middle Age | 2019 |
Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study.
Topics: Administration, Cutaneous; Adult; Antioxidants; Female; Humans; Hydroquinones; Melanosis; Middle Age | 2019 |
A novel triple combination in treatment of melasma: Significant outcome with far less actives.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Diagnostic Self Evaluation; Dicarboxylic Acid | 2019 |
A New HPLC-DAD Method for the Concurrent Determination of Hydroquinone, Hydrocortisone Acetate and Tretinoin in Different Pharmaceuticals for Melasma Treatment.
Topics: Chromatography, High Pressure Liquid; Dermatologic Agents; Drug Combinations; Humans; Hydrocortisone | 2019 |
Efficacy of hydroquinone-free skin-lightening cream for photoaging.
Topics: Administration, Cutaneous; Adult; Aged; California; Dermatologic Agents; Drug Combinations; Female; | 2013 |
Silicone sheet containing all-trans retinoic acid and hydroquinone for the treatment of epidermal melanosis.
Topics: Adult; Aged; Antioxidants; Drug Therapy, Combination; Female; Humans; Hydroquinones; Keratolytic Age | 2013 |
Blockade of melanin synthesis, activation and distribution pathway by a nonprescription natural regimen is equally effective to a multiple prescription-based therapeutic regimen.
Topics: Adult; Biological Products; Dermatologic Agents; Female; Follow-Up Studies; Humans; Hydroquinones; H | 2013 |
Exogenous ochronosis in a Chinese patient: use of dermoscopy aids early diagnosis and selection of biopsy site.
Topics: Alkaptonuria; Biopsy; Bleaching Agents; China; Dermoscopy; Humans; Hydroquinones; Male; Melanosis; M | 2014 |
Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs.
Topics: Animals; Hydrolysis; Hydroquinones; Melanosis; Mice; Molecular Docking Simulation; Monophenol Monoox | 2014 |
Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma.
Topics: Dermatologic Agents; Dermoscopy; Female; Glycolates; Humans; Hyaluronic Acid; Hydroquinones; Melanos | 2015 |
Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
Topics: Administration, Cutaneous; Adult; Aged; Drug Compounding; Drug Therapy, Combination; Female; Humans; | 2016 |
A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Combined Modality Therapy; Erythema; Facial | 2017 |
Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
Topics: Administration, Cutaneous; Adult; Aged; Drug Compounding; Drug Therapy, Combination; Female; Humans; | 2016 |
Exogenous Ochronosis in Facial Melasma.
Topics: Dermoscopy; Facial Dermatoses; Female; Homogentisate 1,2-Dioxygenase; Homogentisic Acid; Humans; Hyd | 2017 |
Anti-melasma codrug of retinoic acid assists cutaneous absorption with attenuated skin irritation.
Topics: Administration, Cutaneous; Animals; Drug Combinations; Female; Hydrolysis; Hydroquinones; Interleuki | 2017 |
Exogenous ochronosis.
Topics: Dermatologic Agents; Diagnosis, Differential; Facial Dermatoses; Female; Humans; Hydroquinones; Mela | 2008 |
Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Cost-Benefit Analysis; Dermatologic Agents; Dru | 2010 |
Tolerability and efficacy of a novel formulation in the treatment of melasma.
Topics: Adult; Dermatologic Agents; Drug Therapy, Combination; Female; Glycolates; Humans; Hyaluronic Acid; | 2010 |
Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
Topics: Administration, Topical; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Combinations; F | 2010 |
Exogenous ochronosis in Asians.
Topics: Antioxidants; Asian People; Humans; Hydroquinones; Melanosis; Ochronosis; Pigmentation Disorders | 2010 |
Triple combination and glycolic acid peels in melasma in Indian patients.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Antioxidants; Chemexfoliation; Drug Combin | 2011 |
Treatment of hyperpigmentation.
Topics: Anisoles; Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroqu | 2011 |
Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis.
Topics: Adult; Dermoscopy; Humans; Hydroquinones; Male; Melanosis; Ochronosis | 2013 |
Lustra, Lustra-AF and Alustra.
Topics: Drug Therapy, Combination; Humans; Hydroquinones; Hyperpigmentation; Melanosis; Tretinoin | 2003 |
[LEUCOMELANODERMA CAUSED BY HYDROQUINONE].
Topics: Colonic Diseases; Humans; Hydroquinones; Melanosis; Phenols; Pigmentation Disorders; Toxicology | 1965 |
Treatment of chloasma with monobenzyl ether of hydroquinone.
Topics: Ether; Ethers; Humans; Hydroquinones; Melanosis; Pigmentation; Quinones | 1951 |
4% hydroquinone versus 4% hydroquinone, 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma: a comparative study.
Topics: Administration, Topical; Dermatologic Agents; Dexamethasone; Drug Combinations; Humans; Hydroquinone | 2005 |
Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma.
Topics: Adult; Face; Humans; Hydroquinones; Male; Melanosis; Pseudolymphoma; Skin Diseases | 2005 |
Repeated treatment protocols for melasma and acquired dermal melanocytosis.
Topics: Adult; Antioxidants; Asian People; Combined Modality Therapy; Drug Therapy, Combination; Facial Neop | 2006 |
Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.
Topics: Adult; Drug Therapy, Combination; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; Hydroquin | 2006 |
Therapeutical approaches in melasma.
Topics: Chemexfoliation; Cosmetics; Dermatologic Agents; Dicarboxylic Acids; Drug Combinations; Humans; Hydr | 2007 |
Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy.
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Dermoscopy; Female; Humans; Hydroquinones; Hy | 2008 |
An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
Topics: Administration, Topical; Adult; Antioxidants; Female; Fluocinolone Acetonide; Humans; Hydroquinones; | 2007 |
Use of hydroquinone as a bleaching cream.
Topics: Chemistry, Pharmaceutical; Humans; Hydroquinones; Melanosis; Ointments; Pigmentation Disorders | 1993 |
[Minor symptoms in family medicine; chloasma or 'pregnancy mask'].
Topics: Female; Humans; Hydroquinones; Melanosis; Ointments; Pigmentation Disorders; Pregnancy; Radiation-Pr | 1995 |
The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions.
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Drug Therapy, Combination; Female; Glycolates; Huma | 1996 |
Efficacy of hydroquinone in the treatment of cutaneous hyperpigmentation in hairless descendants of Mexican hairless dogs (Xoloitzcuintli).
Topics: Animals; Animals, Newborn; Cell Count; Dihydroxyphenylalanine; Dog Diseases; Dogs; Female; Hydroquin | 1998 |
Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Clinical Trials as Topic; Drug Combinations; Female; | 2001 |
[Clinical evaluation of the efficacy of a topical preparation containing 2% hydroquinone in chloasma].
Topics: Administration, Topical; Adult; Facial Dermatoses; Female; Humans; Hydroquinones; Melanosis; Middle | 1987 |